VCYT logo

VCYTVeracyte Inc

$47.23
$0.19
(0.40%)
Today
Updated: 10:27 AM EDT
EarningsAug 5
Mkt Cap$3.78B
Vol97,271.00
News
all
press releases
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
More News
News Placeholder
Why Is Steris (STE) Up 1% Since Last Earnings Report?
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Zacks
News Placeholder
Here's Why Veracyte (VCYT) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
VCYT Crosses Above Average Analyst Target
In recent trading, shares of Veracyte Inc (Symbol: VCYT) have crossed above the average analyst 12-month target price of $48.80, changing hands for $49.94/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuati...
Nasdaq News: Markets
News Placeholder
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the U.S. commercial launch of the Prosigna Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with...
Business Wire
News Placeholder
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate test identifies which men with metastatic prostate cancer benefit from adding the...
Business Wire
News Placeholder
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracytes Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today results from the independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (UCL). The results, which will be presented at the...
Business Wire
News Placeholder
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.
Zacks
<
1
2
...
>

Advertisement|Remove ads.